Therapeutic Silencing of KRAS using Systemically Delivered siRNAs

Despite being amongst the most common oncogenes in human cancer, to date there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS mutated cancer models. We identified KRAS siRNA sequences with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Autores principales: Pecot, Chad V., Wu, Sherry Y., Bellister, Seth, Filant, Justyna, Rupaimoole, Rajesha, Hisamatsu, Takeshi, Bhattacharya, Rajat, Maharaj, Anshumaan, Azam, Salma, Rodriguez-Aguayo, Cristian, Nagaraja, Archana S., Morelli, Maria Pia, Gharpure, Kshipra M., Waugh, Trent A., Gonzalez-Villasana, Vianey, Zand, Behrouz, Dalton, Heather J., Kopetz, Scott, Lopez-Berestein, Gabriel, Ellis, Lee M., Sood, Anil K.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4416486/
https://ncbi.nlm.nih.gov/pubmed/25281617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0074
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares